These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32076805)

  • 21. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.
    Del Rosso JQ
    J Clin Aesthet Dermatol; 2014 Jul; 7(7):10-8. PubMed ID: 25053979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole.
    Pollak RA; Ilie C
    J Drugs Dermatol; 2017 Dec; 16(12):1269-1273. PubMed ID: 29240863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efinaconazole in Onychomycosis.
    Gupta AK; Talukder M
    Am J Clin Dermatol; 2022 Mar; 23(2):207-218. PubMed ID: 34902110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tavaborole topical solution (Kerydin) for onychomycosis.
    Med Lett Drugs Ther; 2015 Mar; 57(1463):35-6. PubMed ID: 25719999
    [No Abstract]   [Full Text] [Related]  

  • 25. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
    Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
    Bhatt V; Pillai R
    J Pharm Sci; 2015 Jul; 104(7):2177-82. PubMed ID: 25940933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies.
    Gupta AK; Hall S; Zane LT; Lipner SR; Rich P
    J Dermatolog Treat; 2018 Feb; 29(1):44-48. PubMed ID: 28521541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice.
    Rich P; Vlahovic TC; Joseph WS; Zane LT; Hall SB; Gellings Lowe N; Adigun CG
    Cutis; 2017 Oct; 100(4):259-264. PubMed ID: 29136060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail.
    Lipner SR; Scher RK
    Expert Rev Clin Pharmacol; 2015; 8(6):719-31. PubMed ID: 26325488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efinaconazole topical solution (Jublia) for onychomycosis.
    Med Lett Drugs Ther; 2014 Sep; 56(1451):88-9. PubMed ID: 25211303
    [No Abstract]   [Full Text] [Related]  

  • 31. Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study.
    Rich P; Spellman M; Purohit V; Zang C; Crook TJ
    J Drugs Dermatol; 2019 Feb; 18(2):190-195. PubMed ID: 30811142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vitro Nail Penetration and Antifungal Activity of Tavaborole, a Boron-Based Pharmaceutical.
    Coronado D; Merchant T; Chanda S; Zane LT
    J Drugs Dermatol; 2015 Jun; 14(6):609-14. PubMed ID: 26091387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing topical therapy for onychomycosis: the importance of patient education.
    Lipner SR; Ko D
    Cutis; 2018 Dec; 102(6):389-390. PubMed ID: 30657804
    [No Abstract]   [Full Text] [Related]  

  • 34. Onychomycosis in children - review on treatment and management strategies.
    Gupta AK; Venkataraman M; Shear NH; Piguet V
    J Dermatolog Treat; 2022 May; 33(3):1213-1224. PubMed ID: 32799713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JUBLIA (Efinaconazole 10% Solution) in the Treatment of Pediatric Onychomycosis.
    Gupta AK; Venkataraman M; Abramovits W; Guenin EP
    Skinmed; 2021; 19(3):206-210. PubMed ID: 34303391
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Kubota-Ishida N; Takei-Masuda N; Kaneda K; Nagira Y; Chikada T; Nomoto M; Tabata Y; Takahata S; Maebashi K; Hui X; Maibach HI
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
    Aly R; Gupta AK; Winter T; Zane LT; Vlahovic T
    J Drugs Dermatol; 2017 Oct; 16(10):1016-1021. PubMed ID: 29036255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical Tavaborole in the Treatment of Onychomycosis Complicated by Dermatophytoma: A Post-hoc Assessment of Phase II Subjects.
    Aly R; Winter T; Hall S; Vlahovic T
    J Drugs Dermatol; 2018 Mar; 17(3):347-354. PubMed ID: 29537453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.
    Pollak RA
    J Am Podiatr Med Assoc; 2014 Nov; 104(6):568-73. PubMed ID: 25514267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
    Gupta AK; Fleckman P; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.